Novo Nordisk A/S (NYSE:NVO) Shares Sold by Breakwater Capital Group

Breakwater Capital Group lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 10.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,555 shares of the company’s stock after selling 300 shares during the period. Breakwater Capital Group’s holdings in Novo Nordisk A/S were worth $220,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of NVO. Wallace Advisory Group LLC raised its holdings in Novo Nordisk A/S by 8.7% in the 4th quarter. Wallace Advisory Group LLC now owns 11,641 shares of the company’s stock worth $1,001,000 after purchasing an additional 930 shares during the period. Signal Advisors Wealth LLC raised its holdings in Novo Nordisk A/S by 39.1% in the 4th quarter. Signal Advisors Wealth LLC now owns 15,874 shares of the company’s stock worth $1,365,000 after purchasing an additional 4,464 shares during the period. AAFMAA Wealth Management & Trust LLC raised its holdings in Novo Nordisk A/S by 35.2% in the 4th quarter. AAFMAA Wealth Management & Trust LLC now owns 17,357 shares of the company’s stock worth $1,493,000 after purchasing an additional 4,519 shares during the period. Tealwood Asset Management Inc. raised its holdings in Novo Nordisk A/S by 1.6% in the 4th quarter. Tealwood Asset Management Inc. now owns 14,336 shares of the company’s stock worth $1,233,000 after purchasing an additional 220 shares during the period. Finally, AdvisorNet Financial Inc raised its holdings in Novo Nordisk A/S by 24.8% in the 4th quarter. AdvisorNet Financial Inc now owns 2,791 shares of the company’s stock worth $240,000 after purchasing an additional 554 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 4.0 %

Shares of Novo Nordisk A/S stock opened at $81.27 on Wednesday. The firm has a market capitalization of $364.70 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $80.05 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a 50 day moving average of $99.26 and a 200 day moving average of $118.18.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.